← Leaderboards
Tanya Kalin
Cincinnati Childrens Hosp Med Ctr
$7,313,192
Attributed
$8,377,585
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,377,585 · 6
By mechanism
R01$7,987,585 · 5
R56$390,000 · 1
Top collaborators
- Vladimir V Kalinichenko5 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Lisa R. Young$7,622,335
- Mingxia Gu$2,390,591
- Derek S Wheeler$754,750
- Yan Xu$6,358,233
- Matthew Riccetti$148,310
Others in their field
Top investigators on “Signal Pathway”
- David Heimbrook · Leidos Biomedical Research, Inc.$191,912,844
- Asrar B. Malik · University Of Illinois At Chicago$75,811,832
- Robert H Tukey · University Of California San Diego$50,504,865
- Meenhard Herlyn · University Of Pennsylvania$50,308,097
- Ian A Wilson · Scripps Research Institute, The$50,300,809
- Richard D Smith · Battelle Pacific Northwest Laboratories$46,192,560
Research focus
Signal PathwayCellsLungTranscription FactorMouse ModelTransgenic MiceGenesPreventSignal TransductionNovel Therapeutic InterventionGenetic TranscriptionLaboratoriesEndothelial CellsFibroblastsInflammatoryMolecularIn VitroEpithelial CellsGeneticMacrophagePlaySingle-Cell Rna SequencingProliferatingInflammation Mediators
Grant awards (21)
Theraputic targeting of pulmonary endothelial cells to inhibit pathological lung remodeling$695,403
R01 · FY2025 · HL · contact PI
Role of lung endothelial cells during fibrotic lung remodeling$521,087
R01 · FY2024 · HL · contact PI
Development of novel therapeutic approaches for treatment of Alveolar Capillary Dysplasia$510,389
R01 · FY2024 · HL
Development of novel therapeutic approaches for treatment of Alveolar Capillary Dysplasia$531,604
R01 · FY2023 · HL
Role of lung endothelial cells during fibrotic lung remodeling$349,928
R01 · FY2023 · HL · contact PI
Role of lung endothelial cells during fibrotic lung remodeling.$188,307
R01 · FY2023 · HL · contact PI
Development of novel therapeutic approaches for treatment of Alveolar Capillary Dysplasia$7,862
R01 · FY2023 · HL
Role of lung endothelial cells during fibrotic lung remodeling.$550,773
R01 · FY2022 · HL · contact PI
Development of novel therapeutic approaches for treatment of Alveolar Capillary Dysplasia$539,466
R01 · FY2022 · HL
Role of lung endothelial cells during fibrotic lung remodeling.$550,773
R01 · FY2021 · HL · contact PI
Development of novel therapeutic approaches for treatment of Alveolar Capillary Dysplasia$539,466
R01 · FY2021 · HL
Targeting Foxm1 in pulmonary fibrosis$390,000
R01 · FY2019 · HL · contact PI
Targeting Foxm1 in pulmonary fibrosis$390,000
R01 · FY2018 · HL · contact PI
Targeting Foxm1 in pulmonary fibrosis$390,000
R01 · FY2017 · HL · contact PI
Targeting Foxm1 in pulmonary fibrosis$312,000
R01 · FY2016 · HL · contact PI
Transcriptional regulation of pulmonary fibrosis$390,000
R56 · FY2015 · HL · contact PI
Role of Foxm1 in Lung Cancer Microenvironment$298,713
R01 · FY2014 · CA · contact PI
Role of Foxm1 in Lung Cancer Microenvironment$289,474
R01 · FY2013 · CA · contact PI
Role of Foxm1 in Lung Cancer Microenvironment$307,951
R01 · FY2012 · CA · contact PI
Role of Foxm1 in Lung Cancer Microenvironment$307,951
R01 · FY2011 · CA · contact PI
Role of Foxm1 in Lung Cancer Microenvironment$316,438
R01 · FY2010 · CA · contact PI